Nexvet acquired by Zoetis for $85m

2018-08-01T15:39:53+01:00

The Irish Times - Zoetis pays $85m for Irish petcare biopharma Nexvet Please link to the article below by Dominic Coyle which was posted in Apr 2017 by irishtimes.com/business page. Nexvet, the Irish pet pharmaceutical group, had an unusual structure, with the company conducting its drug discovery in Australia, undertaking clinical trials in the United States and Europe, and manufacturing the drugs in Ireland for sale into international markets. The US animal health company, Zoetis has agreed to pay $6.72 per share through Zoetis Bidco, which values Nexvet at $85m. You can access further information by reading the full article [...]

Nexvet acquired by Zoetis for $85m2018-08-01T15:39:53+01:00

The Australian – Nexvet Investment

2018-08-01T14:10:23+01:00

The Australian - Nexvet raises $US31.5m Please link to the article below which was posted in Apr 2014 by theaustralian.com.au website. Nexvet, founded in 2010 and headquartered in Tullamore, Ireland, is a biologic therapeutics company with therapies being developed for companion animals. The company has research and development operations in Melbourne, Australia, a manufacturing facility in Tullamore. The articles reports a significant investment from US-based institutional investors and existing shareholders to advance its clinical programs. You can read the full article by clicking on the button below. The Australian Article - "Nexvet raises $US31.5m" [...]

The Australian – Nexvet Investment2018-08-01T14:10:23+01:00
Go to Top